Table 1.
Basic characteristics of included studies.
| Study | Country | Participants | Sample size | Male/% | Age/years | Disease duration/years | NYHA heart function classification | Intervention | Treatment duration/weeks |
|---|---|---|---|---|---|---|---|---|---|
| Cai (18) | China | Chinese | 52 | 53.8 | 61.3 | / | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.54 g tid |
1 |
| 52 | 57.7 | 61.4 | / | Conventional treatment | 1 | ||||
| Chen and Ye (19) | China | Chinese | 75 | / | / | / | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
12 |
| 75 | / | / | / | Conventional treatment | 12 | ||||
| Hou and Zhou (20) | China | Chinese | 42 | 59.5 | 65.5 | 5.4 | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
2 |
| 42 | 64.3 | 65.4 | 5.3 | Conventional treatment | 2 | ||||
| Huang et al. (21) | China | Chinese | 63 | 58.7 | 65.8 | / | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
4 |
| 63 | 57.1 | 65.5 | / | Conventional treatment | 4 | ||||
| Li and Liao (22) | China | Chinese | 60 | 58.3 | 68.0 | / | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
4 |
| 60 | 66.7 | 66.0 | / | Conventional treatment | 4 | ||||
| Li and Yang (23) | China | Chinese | 51 | 62.7 | 53.9 | 2.3 | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
4 |
| 51 | 58.8 | 53.5 | 2.3 | Conventional treatment | 4 | ||||
| Ren et al. (24) | China | Chinese | 98 | 49.0 | 63.2 | 6.5 | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
2 |
| 98 | 52.0 | 63.1 | 6.3 | Conventional treatment | 2 | ||||
| Shen et al. (25) | China | Chinese | 48 | 58.3 | 56.5 | 5.1 | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
2 |
| 48 | 54.2 | 57.9 | 5.0 | Conventional treatment | 2 | ||||
| Wang (26) | China | Chinese | 30 | 63.3 | 71.7 | / | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
4 |
| 30 | 50.0 | 70.6 | / | Conventional treatment | 4 | ||||
| Wu et al. (27) | China | Chinese | 41 | 51.2 | 59.1 | 6.0 | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
8 |
| 41 | 46.3 | 58.2 | 5.4 | Conventional treatment | 8 | ||||
| Wu (28) | China | Chinese | 46 | 54.3 | 68.5 | 8.2 | I–Ⅱ | Conventional treatment DZSM Capsule 0.36 g tid |
4 |
| 46 | 60.9 | 69.4 | 7.9 | Conventional treatment | 4 | ||||
| Zhan et al. (29) | China | Chinese | 45 | 60.0 | 56.8 | 7.2 | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
8 |
| 45 | 66.7 | 56.7 | 7.1 | Conventional treatment | 8 | ||||
| Zhang (30) | China | Chinese | 64 | 54.7 | 66.0 | 2.9 | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
8 |
| 64 | 53.1 | 65.6 | 3.0 | Conventional treatment | 8 | ||||
| Zhang (31) | China | Chinese | 43 | 53.5 | 63.3 | 7.9 | Ⅱ–Ⅲ | Conventional treatment DZSM Capsule 0.36 g tid |
2 |
| 43 | 51.2 | 63.3 | 7.9 | Conventional treatment | 2 | ||||
| Zhou et al. (32) | China | Chinese | 45 | 51.1 | 54.6 | 2.8 | Ⅱ–Ⅳ | Conventional treatment DZSM Capsule 0.36 g tid |
8 |
| 45 | 44.4 | 55.9 | 3.2 | Conventional treatment | 8 |
DZSMC, Dengzhan Shengmai capsule.